Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

XML

Research Article

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Online download statistics by month:

Online download statistics by month: December 2019 to May 2022

	Abstract	Full	Pdf
Dec 2019	2	2	0
Jan 2020	5	5	0
Feb 2020	16	16	5
Mar 2020	33	33	2
Apr 2020	37	37	2
May 2020	49	49	12
Jun 2020	29	29	2
Jul 2020	30	31	3
Aug 2020	15	15	9
Sep 2020	33	33	2
Oct 2020	38	38	10
Nov 2020	95	95	1
Dec 2020	13	13	1
Jan 2021	23	23	9
Feb 2021	43	43	4
Mar 2021	38	38	9
Apr 2021	30	30	4
May 2021	15	15	3
Jun 2021	27	27	6
Jul 2021	28	28	9
Aug 2021	23	23	5
Sep 2021	143	144	11
Oct 2021	77	77	4
Nov 2021	64	64	11
Dec 2021	67	67	8
Jan 2022	56	59	4
Feb 2022	40	40	6
Mar 2022	61	61	5
Apr 2022	46	47	10
May 2022	59	63	11
Total	1235	1245	168